Want to see JYNT full AI Analyst Report?
JYNT Stock Chart & Stats
$8.35
$0.22(2.63%)
At close: 4:00 PM EDT
$8.35
$0.22(2.63%)
Day’s Range― - ―
52-Week Range$7.50 - $11.14
Previous Close$8.57
Volume61.03K
Average Volume (3M)133.85K
Market Cap
$119.37M
Enterprise Value$104.15
Total Cash (Recent Filing)$22.16M
Total Debt (Recent Filing)$2.04M
Price to Earnings (P/E)31.8
Beta1.11
Next Earnings
Nov 05, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.27
Shares Outstanding14,143,154
10 Day Avg. Volume93,155
30 Day Avg. Volume133,848
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)8.77
Price to Sales (P/S)2.40
P/FCF Ratio394.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$10.50Price Target Upside25.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.28
Revenue Forecast (FY)$60.29M
Bulls Say, Bears Say
Bulls Say
Capital-light Franchisor TransitionCompleting the transfers should reduce capital requirements and operating complexity. A predominantly royalty-based model can improve margin visibility and scalability over time, provided franchisee economics and clinic retention remain healthy.
Profitability And Cash-flow ReboundThe sharp improvement in EBITDA and cash generation indicates that operating leverage is emerging as the business refranchises. Positive free cash flow provides greater flexibility to fund growth, repurchases, and ongoing strategic investments.
Improving Retention And Pricing PowerBetter retention supports recurring membership revenue and strengthens franchisee unit economics. Broad customer acceptance of price increases suggests the brand retains some pricing power, which can help offset cost inflation and support royalty growth.
Bears Say
Persistently Weak Same-store PerformanceNegative comparable sales indicate that the existing clinic base has not yet regained durable demand momentum. Continued weakness could constrain franchisee profitability, reduce royalty growth, and make retention of operators more difficult.
Reduced Clinic Expansion CadenceLower openings and net clinic contraction reduce the pipeline for future franchise fees and royalty growth. The revised outlook also signals a more selective expansion environment and raises execution risk as underperforming locations are rationalized.
Inconsistent Earnings And Cash-flow DurabilityAlthough TTM profitability has recovered, the multi-year record shows that earnings and cash generation are not yet consistently durable. Historical volatility makes it harder to establish a dependable operating baseline during the refranchising transition.
Joint News
JYNT FAQ
What was Joint Corp’s price range in the past 12 months?
Joint Corp lowest stock price was $7.50 and its highest was $11.14 in the past 12 months.
What is Joint Corp’s market cap?
Joint Corp’s market cap is $119.37M.
When is Joint Corp’s upcoming earnings report date?
Joint Corp’s upcoming earnings report date is Nov 05, 2026 which is in 73 days.
How were Joint Corp’s earnings last quarter?
Joint Corp released its earnings results on Aug 06, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.057.
Is Joint Corp overvalued?
According to Wall Street analysts Joint Corp’s price is currently Undervalued.
Does Joint Corp pay dividends?
Joint Corp does not currently pay dividends.
What is Joint Corp’s EPS estimate?
Joint Corp’s EPS estimate is 0.08.
How many shares outstanding does Joint Corp have?
Joint Corp has 14,143,154 shares outstanding.
What happened to Joint Corp’s price movement after its last earnings report?
Joint Corp reported an EPS of -$0.01 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went up 1.338%.
Which hedge fund is a major shareholder of Joint Corp?
Currently, no hedge funds are holding shares in JYNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Joint Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (25.75% Upside)
$10.50 (25.75% Upside)
Blogger Sentiment
Bullish
JYNT Sentiment 100%
Sector Average 61%
Sector Average 61%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.45%
Trailing 12-Months
Company Description
Joint Corp
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
JYNT Company Deck
JYNT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized material progress toward a capital-light franchisor model with strong improvements in core profitability and cash generation (14% revenue growth, $1.4M adjusted EBITDA gain, 152% increase in operating cash flow), near-term operational wins (best retention in 5+ years, pricing uptake, digital visibility) and disciplined capital allocation (share repurchases, RD buybacks). Offsetting risks include continuing negative comp sales (-2.8%), a 3.7% decline in system-wide sales, elevated marketing spend (+40%), reduced near-term clinic opening cadence, and timing/one-time costs associated with refranchising. Overall, the positives — particularly the sizable cash flow and margin improvements tied to refranchising and retention gains — outweigh the remaining execution and timing headwinds.View all JYNT earnings summariesJYNT Stock 12 Month Forecast
Average Price Target
$10.50
▲(25.75% Upside)
Technical Analysis
Encompass Health
―
US Physical Therapy
―
Surgery Partners
―
DocGo
―
Concentra Group Holdings Parent, Inc.
―
Ownership Overview
14.93% Insiders
13.47% Mutual Funds
43.88% Other Institutional Investors
23.68% Public Companies and
Individual Investors